6 months ago
4
Danish drugmaker Novo Nordisk announced a concern with Emcure Pharma connected Monday to motorboat its Poviztra, semaglutide injection 2.4 mg, successful India.
Poviztra is the 2nd marque of its value nonaccomplishment cause Wegovy that Novo Nordisk volition beryllium launching successful India. It had launched Wegovy (semaglutide injection 2.4 mg) successful the state successful June.
Emcure is present exclusive distributor and commercialized spouse for Poviztra. The collaboration volition fortify the organisation and marketing, peculiarly done pharmacies and successful regions beyond those presently served by Novo Nordisk India, the 2 companies said successful a statement. Emcure shares closed 4.89% higher astatine Rs. 1,427.65 apiece connected the BSE.
“We launched Wegovy successful India a fewer months ago. Now, we are blessed to articulation hands with Emcure Pharma to broaden entree to high-quality, harmless and effectual obesity treatment. This concern brings unneurotic Novo Nordisk’s innovation successful GLP-1 therapies and Emcure’s robust selling and organisation capabilities to amended entree to obesity treatment...” said Jay Thyagarajan, Senior V-P, Region APAC of Novo Nordisk.
Emcure CEO and MD Satish Mehta the company’s beardown knowing of the country’s divers geographical scenery and established selling capabilities would assistance reaching the products to patients who request it the most.
